90,116 Shares of Sanofi $SNY Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in shares of Sanofi (NASDAQ:SNY) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 90,116 shares of the company’s stock, valued at approximately $3,715,000.

Other hedge funds also recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of Sanofi by 11.0% during the 1st quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after acquiring an additional 940,342 shares during the last quarter. Mondrian Investment Partners LTD increased its holdings in Sanofi by 2.3% in the third quarter. Mondrian Investment Partners LTD now owns 5,652,139 shares of the company’s stock valued at $233,038,000 after purchasing an additional 129,575 shares during the last quarter. Royal Bank of Canada lifted its stake in Sanofi by 17.5% in the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock valued at $152,011,000 after buying an additional 470,882 shares during the period. Equity Investment Corp lifted its stake in Sanofi by 1.3% in the third quarter. Equity Investment Corp now owns 2,636,859 shares of the company’s stock valued at $108,718,000 after buying an additional 34,888 shares during the period. Finally, Regal Partners Ltd boosted its holdings in Sanofi by 33.2% during the first quarter. Regal Partners Ltd now owns 2,545,432 shares of the company’s stock worth $122,639,000 after buying an additional 633,782 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Royal Bank Of Canada started coverage on shares of Sanofi in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. Sanford C. Bernstein reiterated a “buy” rating on shares of Sanofi in a report on Monday, August 3rd. Wolfe Research began coverage on shares of Sanofi in a research report on Friday, October 9th. They set a “peer perform” rating on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average price target of $53.00.

Sanofi Stock Up 0.1%

Sanofi stock opened at $48.46 on Friday. The company has a 50 day moving average of $42.60 and a 200-day moving average of $44.37. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20. Sanofi has a twelve month low of $39.07 and a twelve month high of $52.68. The stock has a market capitalization of $117.49 billion, a PE ratio of 23.99, a price-to-earnings-growth ratio of 1.33 and a beta of 0.31.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.48. The firm had revenue of $17.25 billion during the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The company’s revenue for the quarter was up 16.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.91 EPS. On average, equities research analysts anticipate that Sanofi will post 5.07 EPS for the current fiscal year.

Sanofi Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.